October 14, 2020
2 min watch
Save
VIDEO: Zeposia meets multiple efficacy endpoints in UC
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this exclusive video, William Sandborn, MD, from the University of California, San Diego, discusses research presented at UEG Week Virtual that explored the safety and efficacy of Zeposia in ulcerative colitis.
In the True North study, researchers found that Zeposia (ozanimod, Bristol-Myers Squibb) sphingosine-1-phosphate receptor subtype 1 modulator, had durable efficacy in clinical, endoscopic, histologic and biomarker endpoints. Additionally, they identified no new safety risks.
Editor's note: The article was updated on Oct. 15, to include the correct name of the study.
Published by:
Sources/Disclosures
Collapse
Source:
Danese S, et al. Abstract LB10. Presented at UEG Week Virtual. Oct. 11-13, 2020.
Sandborn WJ, et al. Abstract LB02. Presented at: UEG Week Virtual. Oct 11-13, 2020.
Disclosures:
Please see the study abstract for Sandborn's full financial disclosures.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.